Physician profile
John P Overholt
NPI 1407841430
$5,160.02
in general payments reported to CMS, 2019-2025
25 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $250 · 2021: $190 · 2022: $517 · 2023: $1,122 · 2024: $1,263 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,020 · Consulting Fee: $32.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,019.92 |
| Consulting Fee | $32.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,238.51 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $781.63 | 2019-2025 | |
| Csl Behring | $506.00 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Glaxosmithkline, LLC. | $354.59 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $332.60 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $322.99 | 2019-2025 | |
| Amgen INC. | $320.46 | 2022-2025 | Tezspire |
| Genentech USA, INC. | $252.47 | 2019-2025 | Xolair |
| Pfizer INC. | $172.95 | 2020-2025 | |
| Olympus America INC. | $119.92 | 2020 | |
| Cycle Pharmaceuticals INC | $102.99 | 2024-2025 | Sajazir |
| Leo Pharma INC. | $90.78 | 2022 | |
| Optinose US, INC. | $81.13 | 2022-2025 | |
| Grifols USA, LLC | $81.13 | 2023-2025 | Xembify |
| Lilly USA, LLC | $58.69 | 2025 | Ebglyss |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $49.21 | 2024 | Hyqvia, Cuvitru |
| Biocryst US Sales Co., LLC | $46.03 | 2023-2025 | Orladeyo |
| Phadia US INC. | $44.71 | 2021-2024 | Immunocap |
| Octapharma USA, INC. | $38.44 | 2023-2024 | Cutaquig |
| Azurity Pharmaceuticals, INC. | $34.98 | 2025 | Alvesco |
| Ionis Pharmaceuticals, INC. | $33.02 | 2025 | Dawnzera |
| Adma Biomanufacturing LLC | $32.70 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $27.65 | 2019-2023 | Airduo Digihaler |
| Kaleo, INC. | $23.36 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Overholt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.